Cost-effectiveness analysis of implementing screening on preterm pre-eclampsia at first trimester of pregnancy in Germany and Switzerland

• Published in: PloS one 2022-06, Vol.17 (6), p.e0270490-e0270490
• Main Authors: Mewes, Janne C, Lindenberg, Melanie, Vrijhoef, Hubertus J. M
• Format: Article
• Language: English
• Subjects: Aspirin; Blood pressure; Cost analysis; Cost benefit analysis; Costs; Diagnosis; Diagnosis related groups; Disease prevention; DRGs; Drug dosages; Economic analysis; Economic aspects; Economic models; Evaluation; Health aspects; Health care; Health risks; Medical care, Cost of; Medical screening; Medicine and Health Sciences; Obstetrics; Parameter sensitivity; People and Places; Pre-eclampsia; Preeclampsia; Pregnancy; Pregnant women; Premature birth; Prenatal care; Sensitivity analysis; Social Sciences; Stillbirth; Womens health
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0270490

To assess the cost-effectiveness of preterm preeclampsia (PE) screening versus routine screening based on maternal characteristics in Germany and Switzerland. A health economic model was used to analyse the cost-effectiveness of PE screening versus routine screening based on maternal characteristics. The analysis was conducted from the healthcare perspective with a time horizon of one year from the start of pregnancy. The main outcome measures were incremental health care costs and incremental costs per PE case averted. The incremental health care costs for PE screening versus routine screening per woman were [euro]14 in Germany, and -CHF42 in Switzerland, the latter representing cost savings. In Germany, the incremental costs per PE case averted were [euro]3,795. In Switzerland, PE screening was dominant. The most influential parameter in the one-way sensitivity analysis was the cost of PE screening (Germany) and the probability of preterm PE in routine screening (Switzerland). In Germany, at a willingness-to-pay for one PE case avoided of [euro]4,200, PE screening had a probability of more than 50% of being cost-effective compared to routine screening. In Switzerland, at a willingness-to-pay of CHF0, PE screening had a 78% probability of being the most cost-effective screening strategy. For Switzerland, PE screening is expected to be cost saving in comparison to routine screening. For Germany, the additional health care costs per woman were expected to be [euro]14. Future cost-effectiveness studies should be conducted with a longer time horizon.